Skip header and navigation

Refine By

5515 records – page 1 of 552.

A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults.

https://arctichealth.org/en/permalink/ahliterature15782
Source
Allergy. 1997 Aug;52(8):853-9
Publication Type
Article
Date
Aug-1997
Author
O T Olsen
K R Larsen
L. Jacobsan
U G Svendsen
Author Affiliation
Department of Pulmonery Medicine and Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Source
Allergy. 1997 Aug;52(8):853-9
Date
Aug-1997
Language
English
Publication Type
Article
Keywords
Adolescent
Adrenergic beta-Agonists - therapeutic use
Adult
Antigens, Dermatophagoides
Asthma - diagnosis - drug therapy - therapy
Bronchial Provocation Tests
Double-Blind Method
Female
Forced expiratory volume
Glycoproteins - administration & dosage - adverse effects - immunology
Humans
Immunoglobulin E - analysis - blood - immunology
Immunotherapy
Male
Middle Aged
Peak Expiratory Flow Rate
Severity of Illness Index
Skin Tests
Steroids - therapeutic use
Vital Capacity
Abstract
Thirty-one adult patients with asthma caused by house-dust mites (HDM) were included in this placebo-controlled, double-blind study to evaluate the efficacy and safety of specific immunotherapy (SIT) with biologically standardized extracts of HDM. The specific diagnosis was confirmed by skin prick tests, specific IgE, and bronchial provocation tests with HDM allergens. The patients were randomized to receive active treatment with extracts of either Dermatophagoides pteronyssinus (Dpt) or D. farinae (Dfa) (Alutard SQ, ALK, Denmark) or placebo injections. Twenty-three patients completed the study. After 1 year of treatment, we found a clinically important and significant reduction in both asthma medicine consumption (inhaled steroids 38% and beta 2-agonists 46%) and symptom score (57%) in the actively treated group, but not the placebo group. These findings were confirmed by a significant decrease in skin and bronchial sensitivity to HDM in the active group. Additionally, there was a significant difference in the patients' scores for effect in favor of the actively treated group. Total IgE and specific IgE to HDM showed no significant changes before and after treatment for either group. Spirometric lung-function measurements showed a significant increase in forced expiratory volume in 1 s (FEV1) from 85% before to 89% of predicted values after treatment for the actively treated group. Peak-flow measurements at home showed no significant changes during the study. It is concluded that allergen SIT is an effective treatment in adult patients suffering from asthma due to HDM.
PubMed ID
9284985 View in PubMed
Less detail

1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.

https://arctichealth.org/en/permalink/ahliterature186500
Source
Lancet. 2003 Feb 22;361(9358):662-8
Publication Type
Article
Date
Feb-22-2003
Author
Johan Kakko
Kerstin Dybrandt Svanborg
Mary Jeanne Kreek
Markus Heilig
Author Affiliation
Division of Psychiatry, Neurotec, Karolinska Institute, Huddinge University Hospital, S-141 86, Stockholm, Sweden.
Source
Lancet. 2003 Feb 22;361(9358):662-8
Date
Feb-22-2003
Language
English
Publication Type
Article
Keywords
Adult
Buprenorphine - therapeutic use
Counseling
Female
Heroin Dependence - classification - drug therapy - prevention & control
Humans
Male
Narcotic Antagonists - therapeutic use
Psychotherapy, Group
Severity of Illness Index
Sweden
Treatment Outcome
Abstract
The partial opiate-receptor agonist buprenorphine has been suggested for treatment of heroin dependence, but there are few long-term and placebo-controlled studies of its effectiveness. We aimed to assess the 1-year efficacy of buprenorphine in combination with intensive psychosocial therapy for treatment of heroin dependence.
40 individuals aged older than 20 years, who met DSM-IV criteria for opiate dependence for at least 1 year, but did not fulfil Swedish legal criteria for methadone maintenance treatment were randomly allocated either to daily buprenorphine (fixed dose 16 mg sublingually for 12 months; supervised daily administration for a least 6 months, possible take-home doses thereafter) or a tapered 6 day regimen of buprenorphine, thereafter followed by placebo. All patients participated in cognitive-behavioural group therapy to prevent relapse, received weekly individual counselling sessions, and submitted thrice weekly supervised urine samples for analysis to detect illicit drug use. Our primary endpoint was 1-year retention in treatment and analysis was by intention to treat.
1-year retention in treatment was 75% and 0% in the buprenorphine and placebo groups, respectively (p=0.0001; risk ratio 58.7 [95% CI 7.4-467.4]). Urine screens were about 75% negative for illicit opiates, central stimulants, cannabinoids, and benzodiazepines in the patients remaining in treatment.
The combination of buprenorphine and intensive psychosocial treatment is safe and highly efficacious, and should be added to the treatment options available for individuals who are dependent on heroin.
Notes
Comment In: Lancet. 2003 May 31;361(9372):1907; author reply 1907-812788596
Comment In: Lancet. 2003 Feb 22;361(9358):634-512606172
Comment In: Lancet. 2003 May 31;361(9372):1906-7; author reply 1907-812788595
PubMed ID
12606177 View in PubMed
Less detail

[2nd place in the contest for young scientists on gastroenterology in the 17th Congress "Man and Medicine" (April 2010, Moscow). Erosive esophagitis in children: characteristics of 24-hour pH monitoring in the the esophagus].

https://arctichealth.org/en/permalink/ahliterature146414
Source
Eksp Klin Gastroenterol. 2010;(9):129-36
Publication Type
Article
Date
2010

3-Year follow-up of secondary chronic headaches: the Akershus study of chronic headache.

https://arctichealth.org/en/permalink/ahliterature141854
Source
Eur J Pain. 2011 Feb;15(2):186-92
Publication Type
Article
Date
Feb-2011
Author
Kjersti Aaseth
Ragnhild Berling Grande
Jurate Ĺ altyte Benth
Christofer Lundqvist
Michael Bjørn Russell
Author Affiliation
Head and Neck Research Group, Research Centre, Akershus University Hospital, 1478 Lørenskog, Norway. kjersti.aaseth@medisin.uio.no
Source
Eur J Pain. 2011 Feb;15(2):186-92
Date
Feb-2011
Language
English
Publication Type
Article
Keywords
Adult
Chronic Disease
Cross-Sectional Studies
Female
Headache Disorders, Secondary - etiology - physiopathology
Health Surveys
Humans
Male
Norway
Pain Measurement
Questionnaires
Rhinitis - complications
Severity of Illness Index
Sinusitis - complications
Abstract
The objective was to investigate the 3-year course of secondary chronic headaches (?15days per month for at least 3months) in the general population. An age and gender stratified random sample of 30,000 persons aged 30-44years from the general population received a mailed questionnaire. All with self-reported chronic headache, 517 in total, were interviewed by neurological residents. The questionnaire response rate was 71%. The rate of participation in the initial and follow-up interview was 74% (633/852) and 87% (83/95) respectively. The International Classification of Headache Disorders was used, and then in the next step the Cervicogenic Headache International Study Group and American Academy of Otolaryngology criteria were used in relation to cervicogenic headache (CEH) and headache attributed to chronic rhinosinusitis (HACRS). Of those followed-up, 40 had headache attributed to head and/or neck trauma (chronic posttraumatic headache), 0 had CEH and 0 had HACRS according to the ICHD-II criteria, while 18 had CEH according to the Cervicogenic Headache International Study Group's criteria, and 37 had HACRS according to the criteria of the American Academy of Otolaryngology. The headache index (frequency×intensity×duration) was significantly reduced from baseline to follow-up in chronic posttraumatic headache and HACRS, but not in CEH. We conclude that secondary chronic headaches seem to have various course dependent of subtype. Recognizing the different types of secondary chronic headaches is of importance because it might have management implications.
PubMed ID
20667753 View in PubMed
Less detail

5-year outcome after transcatheter aortic valve implantation.

https://arctichealth.org/en/permalink/ahliterature117830
Source
J Am Coll Cardiol. 2013 Jan 29;61(4):413-9
Publication Type
Article
Date
Jan-29-2013
Author
Stefan Toggweiler
Karin H Humphries
May Lee
Ronald K Binder
Robert R Moss
Melanie Freeman
Jian Ye
Anson Cheung
David A Wood
John G Webb
Author Affiliation
St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Source
J Am Coll Cardiol. 2013 Jan 29;61(4):413-9
Date
Jan-29-2013
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Aortic Valve - physiopathology - surgery - ultrasonography
Aortic Valve Stenosis - diagnosis - epidemiology - physiopathology - surgery
Canada - epidemiology
Equipment Failure Analysis - statistics & numerical data
Female
Heart Valve Prosthesis Implantation - adverse effects - methods - mortality - statistics & numerical data
Humans
Male
Outcome and Process Assessment (Health Care)
Postoperative Period
Prognosis
Prosthesis Design
Prosthesis Failure - etiology
Risk factors
Severity of Illness Index
Survival Rate
Survivors - statistics & numerical data
Time Factors
Treatment Outcome
Abstract
The purpose of this study was to investigate the 5-year outcome following transcatheter aortic valve implantation (TAVI).
Little is known about long-term outcomes following TAVI.
The 5-year outcomes following successful TAVI with a balloon-expandable valve were evaluated in 88 patients. Patients who died within 30 days after TAVI were excluded.
Mean aortic valve gradient decreased from 46 ± 18 mm Hg to 10 ± 4.5 mm Hg after TAVI and 11.8 ± 5.7 mm Hg at 5 years (p for post-TAVI trend = 0.06). Mean aortic valve area increased from 0.62 ± 0.17 cm(2) to 1.67 ± 0.41 cm(2) after TAVI and 1.40 ± 0.25 cm(2) at 5 years (p for post-TAVI trend
PubMed ID
23265333 View in PubMed
Less detail

6-month CPAP-treatment in a young male patient with severe obstructive sleep apnoea syndrome - a case study from the couple's perspective.

https://arctichealth.org/en/permalink/ahliterature165224
Source
Eur J Cardiovasc Nurs. 2008 Jun;7(2):103-12
Publication Type
Article
Date
Jun-2008
Author
Anders Broström
Peter Johansson
Jan Albers
Jan Wiberg
Eva Svanborg
Bengt Fridlund
Author Affiliation
Department of Medicine and Care, Faculty of Health Sciences, Linköping University, Linköping, Sweden. andbr@imv.liu.se
Source
Eur J Cardiovasc Nurs. 2008 Jun;7(2):103-12
Date
Jun-2008
Language
English
Publication Type
Article
Keywords
Adaptation, Psychological
Adult
Attitude to Health
Continuous Positive Airway Pressure - adverse effects - psychology
Cost of Illness
Fear
Female
Follow-Up Studies
Frustration
Humans
Male
Nursing Methodology Research
Obesity, Morbid - complications
Qualitative Research
Quality of Life - psychology
Questionnaires
Severity of Illness Index
Sleep Apnea, Obstructive - diagnosis - etiology - prevention & control - psychology
Snoring - etiology - psychology
Social Behavior
Spouses - psychology
Stress, Psychological - etiology - psychology
Sweden
Treatment Outcome
Abstract
Obstructive sleep apnoea syndrome (OSAS) is independently associated with an increased risk for hypertension and cardiovascular disease. Continuous positive airway pressure (CPAP) can reduce mortality and morbidity, but low compliance rates are seen.
To explore and describe the experiences of CPAP-treatment in a young male patient with severe OSAS during a 6-month period from the couple's perspective. METHODS AND THE CASE: A single case study with a phenomenographic approach was employed. Diagnostic procedures of OSAS and initiation of treatment with Auto-CPAP, humidifier and a nasal mask were performed during 4 visits. Conceptions were collected at 4 different occasions during the 6-month period (before, and 2 weeks, 3 months, and 6 months after treatment initiation) by means of interviews with a 33-year old male patient and his female partner.
Totally 17 different structural aspects were found to fluctuate during the 6-month period in relation to; influence of stressors, social reactions and adaptation to increase compliance.
An increased knowledge about the influence of stressors, the social reactions, and the adaptation can help healthcare personnel to identify and better understand concerns of other patients and spouses during different time phases of the initial 6-month period of CPAP-treatment.
Notes
Comment In: Eur J Cardiovasc Nurs. 2008 Jun;7(2):89-9018396463
PubMed ID
17291832 View in PubMed
Less detail

6-Thioguanine therapy in Crohn's disease--observational data in Swedish patients.

https://arctichealth.org/en/permalink/ahliterature91993
Source
Dig Liver Dis. 2009 Mar;41(3):194-200
Publication Type
Article
Date
Mar-2009
Author
Almer S H C
Hjortswang H.
Hindorf U.
Author Affiliation
Department of Clinical and Experimental Medicine, Division of Gastroenterology and Hepatology, Faculty of Health Sciences, Linköping University, Linköping, Sweden. sven.almer@lio.se
Source
Dig Liver Dis. 2009 Mar;41(3):194-200
Date
Mar-2009
Language
English
Publication Type
Article
Keywords
6-Mercaptopurine - adverse effects
Adult
Aged
Antimetabolites, Antineoplastic - therapeutic use
Azathioprine - adverse effects
Crohn Disease - drug therapy
Drug resistance
Female
Humans
Immunosuppressive Agents - adverse effects
Male
Middle Aged
Prospective Studies
Remission Induction
Severity of Illness Index
Sweden
Thioguanine - therapeutic use
Young Adult
Abstract
BACKGROUND AND AIMS: Adverse events (AE) leading to discontinuation or dose-reduction of thiopurine therapy (TP) occur in 9-28% of patients with inflammatory bowel disease. 6-Thioguanine (6-TG) has been proposed as an alternative treatment in patients intolerant for azathioprine (AZA), but some concerns have been raised about drug safety. METHODS: We evaluated in a prospective manner the tolerance and efficacy of 6-TG in 23 Crohn's disease (CD) patients (13 men, median age 41 (19-65) years) with prior intolerance (n=18) or resistance (n=5) to AZA and/or 6-mercaptopurine (6-MP). In addition, eight patients had tried mycophenolate mofetil. Seventeen patients (74%) had undergone intestinal resection, often several times. RESULTS: Patients were treated with a median daily dose of 40 mg 6-TG (range 20-60) for 259 (15-2272) days. Seven of 13 patients (54%) with active disease went into remission after 8 (4-26) weeks. Sixteen patients (70%) experienced AE that lead to discontinuation (n=10) after 85 (15-451) days or dose reduction (n=6) after 78 (10-853) days. Ten of 18 patients (56%) with prior TP-intolerance discontinued 6-TG treatment due to AE compared to none of five patients with TP-resistance (p=0.046). Of 13 patients that tolerated 6-TG, eight discontinued the drug due to therapeutic failure (n=5) or safety concerns (n=3). Eight patients (35%) continued treatment beyond 12 months. There was no significant difference in maximum thioguanine nucleotide levels between patients with AE leading to discontinuation/dose reduction and patients without AE, 652 (99-2488) vs. 551 (392-1574) pmol/8 x 10(8) RBC; p=0.80. CONCLUSIONS: In this cohort of CD patients with severe disease failing traditional thiopurine treatment, a small fraction (22%) had long-term benefit of 6-TG-treatment. 6-TG therapy seems to offer a limited therapeutic gain for patients intolerant to both AZA and 6-MP and other treatment options should be considered.
PubMed ID
18799369 View in PubMed
Less detail

7 years experience of photopatch testing with sunscreen allergens in Sweden.

https://arctichealth.org/en/permalink/ahliterature33993
Source
Contact Dermatitis. 1998 Feb;38(2):61-4
Publication Type
Article
Date
Feb-1998
Author
B. Berne
A M Ros
Author Affiliation
Department of Dermatology, University Hospital, Uppsala, Sweden.
Source
Contact Dermatitis. 1998 Feb;38(2):61-4
Date
Feb-1998
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Allergens - administration & dosage - adverse effects
Child
Dermatitis, Allergic Contact - diagnosis - etiology
Dermatitis, Photoallergic - diagnosis - etiology
Female
Humans
Male
Middle Aged
Multicenter Studies
Patch Tests
Severity of Illness Index
Skin - drug effects - pathology - radiation effects
Sunscreening Agents - administration & dosage - adverse effects
Sweden
Ultraviolet Rays - adverse effects
Urticaria - chemically induced
Abstract
Since 1990 7 sunscreen allergens have been included in the standard photopatch protocol at 2 Swedish dermatology clinics. 355 consecutive patients with suspected photosensitivity were tested, and in 28 of these (7.9%), a total of 42 allergic reactions were found. 80% of the reactions were of photocontact origin. The most common allergen was benzophenone-3 (Eusolex 4360), with 15 photocontact and 1 contact allergic reactions, followed by isopropyl dibenzoylmethane (Eusolex 8020) (8 photocontact, 4 contact) and butyl methoxydibenzoylmethane (Parsol 1789), with 6 photocontact reactions. There were 2 cases of photocontact allergy to phenylbenzimidazole sulfonic acid (Eusolex 232), which has not been reported previously. 1 case of contact urticaria from benzophenone-3 was accidentally found. In addition, 21 + reactions of doubtful relevance were noted in 14 patients: 16 on irradiated and 5 on non-irradiated test sites. Among these, irritant and phototoxic reactions may be included. These results indicate that the inclusion of UV filters in the standard photopatch protocol is important. Immediate-type testing for urticaria could also be of value.
PubMed ID
9506215 View in PubMed
Less detail

[10-years caries incidence and intensity dynamics in pregnant women of Derbent city].

https://arctichealth.org/en/permalink/ahliterature120380
Source
Stomatologiia (Mosk). 2012;91(4):60-2
Publication Type
Article
Date
2012
Author
B R Bakhmudov
Z B Alieva
M B Bakhmudov
Source
Stomatologiia (Mosk). 2012;91(4):60-2
Date
2012
Language
Russian
Publication Type
Article
Keywords
Adolescent
Adult
Dagestan - epidemiology
Dental Caries - epidemiology
Female
Humans
Incidence
Pregnancy
Pregnancy Complications - epidemiology
Severity of Illness Index
Young Adult
Abstract
Caries incidence was assessed in pregnant women in 1998, 2003 an 2008 showing the values to be stable. DMF was almost the same in 1998 and 2003, but in 2008 the rate of "F" (filled) element was significantly higher thus confirming growth in motivation for dental treatment after introduction of private dental practices.
PubMed ID
23011338 View in PubMed
Less detail

5515 records – page 1 of 552.